Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368780 | 0.95 | MAPK1 (0.42) | MAPK1 | |
| SCHEMBL19543445 | 0.89 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL16368781 | 0.87 | MAPK1 (0.48) | MAPK1 | |
| SCHEMBL19543423 | 0.85 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL26380327 | 0.80 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL19543427 | 0.76 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL19101028 | 0.76 | MAPK1 (0.39) | MAPK1 | |
| SCHEMBL19101046 | 0.73 | MAPK1 (0.37) | MAPK1 | |
| SCHEMBL1982314 | 0.73 | MAPK1 (0.65) | MAPK1 | |
| SCHEMBL755226 | 0.70 | MAPK1 (0.48) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9855340-B2 | Hydrogel prodrugs | ASCENDIS PHARMA A/S (DK) | 2018-01-02 | — | — | US | disclosed |
| US-20170340774-A1 | POLETHYLENE GLYCOL HYDROGEL INJECTION | SUNBIO INC. (KR) | 2017-11-30 | — | — | US | disclosed |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2017-04-27 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160296600-A1 | Relaxin Prodrugs | ASCENDIS PHARMA RELAXIN DIVISION A/S (DK) | 2016-10-13 | — | — | US | disclosed |
| US-20160089446-A1 | Modified Hydrogels | ASCENDIS PHARMA A/S (DK) | 2016-03-31 | — | — | US | disclosed |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | ASCENDIS PHARMA INC. | 2015-10-22 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ASCENDIS PHARMA INC. | 2015-10-15 | — | — | US | disclosed |
| US-20150258205-A1 | Hydrogel Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150258205-A1 | Hydrogel Prodrugs | ASCENDIS PHARMA GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | Ascendis Pharma Ophthamology Division A/S (DK) | 2015-01-08 | — | — | US | disclosed |
| US-20140155457-A1 | Method of Relieving, Improving, Preventing or Treating Xerostomia | SUNBIO INC. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155457-A1 | Method of Relieving, Improving, Preventing or Treating Xerostomia | GLA, LPO, MUC1 | MAPK1 3570/4885 |
| US-20160089446-A1 | Modified Hydrogels | CD44, DNPH1, PHYKPL | MAPK1 4652/4885 |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | PIGO, MANBA, OAT | MAPK1 3922/4885 |
| US-20170112939-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | MAPK1 3294/4885 |
| US-20150290337-A1 | DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT | ADAMTS13, ADAMTS5, TNF | MAPK1 2851/4885 |
| US-20160296600-A1 | Relaxin Prodrugs | RXFP1, RXFP2, RXFP3 | MAPK1 3848/4885 |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | MAPK1 3555/4885 |
| US-20150258205-A1 | Hydrogel Prodrugs | CD44, DNPH1, PHYKPL | MAPK1 4784/4885 |
| US-20150010634-A1 | PREVENTION AND TREATMENT OF OCULAR CONDITIONS | PDE6C, ALDH1A2, UACA | MAPK1 3294/4885 |
| US-20170312363-A1 | MULTIFUNCTIONALIZED POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREFOR | HDGF, F11, F12 | MAPK1 1476/4885 |
| US-20150297740-A1 | VEGF Neutralizing Prodrugs for the Treatment of Ocular Conditions | VEGFA, KDR, FLT1 | MAPK1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.